Bruhn O, Paul S, Tetens J, Thaller G: The repertoire of equine intestinal -defensins
Of these drugs, glucagon-like peptide 1 receptor (GLP-1R) agonists are more effective and have fewer side effects
For weight management, continuation criteria differ by medication
Therefore, a GLP-1 sensitizer will have a beneficial effect in preventing NASH
The global GLP-1 Weight Loss Drug Market encompasses glucagon-like peptide-1 receptor agonists, dual GIP/GLP-1 agonists, and emerging triple-receptor agonists approved or in development for chronic weight management, type 2 diabetes remission, and metabolic disease intervention
Anti-Inflammatory Action: The peptide reduces pro-inflammatory cytokines while promoting anti-inflammatory responses, helping to minimize tissue damage and swelling